β-catenin inhibitors in cancer therapeutics: intricacies and way forward.

Bioengineered · 2023 · PMC10478749 · PMID 37655825

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

Hence, targeting isolated molecules might not be significant from a therapeutic point of view as the ‘extent’ of pathway impediment or suppression of tumor progression achievable by downregulating a single molecule is debatable.

also in 673 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.